RxDoctor Payments Data

Arlene Palanca

Acute Care · Hillsborough, NJNPI 1598436982

Payments from drug & device makers

$2,196in general payments, 2019–2025

Across 68 payments — averaging $32.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$863
  • Novo Nordisk$656
  • CSL Behring$163
  • Lilly USA, LLC$83
  • Otsuka America Pharmaceutical, Inc.$66
  • UCB, Inc.$65
  • plus $301 from 10 others

What the payments were for

  • Food & beverage$2,196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,196 in reported general payments places this provider in the 85th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$253,871
Medicare patients
359
Services billed
3,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$40,012
RytaryCarbidopa/Levodopa13$15,702
MyrbetriqMirabegron22$10,171
JanuviaSitagliptin Phosphate17$8,983
FarxigaDapagliflozin Propanediol15$6,905
Breo ElliptaFluticasone/Vilanterol15$6,545
Midodrine Hcl55$2,515
Atorvastatin Calcium179$2,292
Levothyroxine Sodium151$1,682
Comfort Ez Pro Safety Pen NdlPen Needle, Diabetic, Safety11$1,576
Enoxaparin Sodium16$1,479
Duloxetine Hcl56$1,420
Amlodipine Besylate116$1,412
Donepezil Hcl75$1,363
Gabapentin72$1,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$40,01276 claims
AstraZenecaFarxiga$863$6,90515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 656 acute care providers in New Jersey.

Other acute care in Hillsborough

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →